Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Booster Immunogenicity Study of S-268024 vs NUVAXOVID (JN.1) in Adults
jRCT2031240717Phase 3Active, not recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Mar 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing S-268024 booster arm with NUVAXOVID (JN.1 variant) booster arm (2 arms). Primary endpoints: SARS-CoV-2 neutralizing antibody titer (JN.1 variant) on day 29 - GMT and SARS-CoV-2 neutralizing antibody seroresponse rate (JN.1 variant) on day 29. Started Mar 2025; status: active, not recruiting.
02
Drugs
S-268024NVX-CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031240717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240717.